Effect of the insertion/deletion polymorphism of the angiotensin- converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 6, 1998, Pages 988-994

  O'Toole, Laurence ^a   Stewart, Michael ^b   Padfield, Paul ^a   Channer, Kevin ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Captopril; Genetic polymorphism; Heart failure; Lisinopril; Renal function

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HUMAN; INTRON; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CAPTOPRIL; CROSS-OVER STUDIES; FEMALE; GENE DELETION; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; LISINOPRIL; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PRESSORECEPTORS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0031673596     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199812000-00017     Document Type: Article

References (44)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Co-Operative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
2. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilatation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. Am J Cardiol 1992;19:842-50.
3. Cohn JN, Johnson G, Ziesche S, et al. Comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
4. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Left Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
6. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
7. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early captopril, oral mononitrate and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
8. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarcto, Miocardio GISSI-3. Effect of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
9. The AIRE study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
10. Garg R, Yusuf S. Overview of randomised trials of angiotensin-converting enzyme inhibitors on the morbidity and mortality in patients with heart failure. JAMA 1995;18:1450-60.
11. Opie LH, ed. Angiotensin-converting enzyme inhibitors: scientific basis for their clinical use. New York: Wiley-Liss, 1992.
12. Davis R, Ribner HS, Keung E, et al. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med 1979;301:117-21.
13. Packer M, Medina N, Yushak M. Efficacy of captopril in low-renin congestive cardiac failure: importance of sustained reactive hyperreninaemia in distinguishing responders from non-responders. Am J Cardiol 1984;54:771-7.
14. Packer M, Medina N, Yushak M, Lee WH. Usefulness of plasma renin activity in predicting survival during long term converting enzyme inhibition in severe chronic haert failure: experience in 100 consecutive patients. Br Heart J 1985;54:298-304.
15. Mettauer B, Rouleau J-L, Bichet D, et al. Differential long term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. Circulation 1986;73:492-502.
16. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
17. Todd GP, Chadwick IG, Higgins KS, Yeo WW, Jackson PR, Ramsay LE. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995;39:131-4.
18. Gottlieb S, Weir MR. Renal effects of angiotensin-converting enzyme inhibitors in congestive heart failure. Am J Cardiol 1990;66:140-21D.
19. Giles TG, Katz R, Sullivan JM, et al. Short and long acting angiotensin converting enzyme inhibitors: a randomised trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989;13:1240-7.
20. Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal impairment during long term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987;106:346-54.
21. Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double-blind controlled trial. Br Heart J 1984;52:530-5.
22. Cleland JGF, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones and metabolic state. Br Heart J 1985;54:305-12.
23. La France ND, Drew HH, Walser M. Radioisotopic measurement of glomerular filtration rate in severe chronic renal failure. J Nucl Med 1988;29:1927-30.
24. Perrone RD, Steinman TI, Beck GJ, et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125-I Iothalamate, 169-Yb DTPA, 99m-Tc DTPA, and inulin. Am J Kidney Dis 1990;16:224-35.
25. O'Brien E, Mee F, Atkins N and O, Malley K. Accuracy of the Spacelabs 90207 determined by the British Hypertension Society protocol. J Hypertens 1991;9:573-4.
26. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin I converting enzyme gene (DCPI). Nucleic Acids Res 1992;20:1433.
27. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischaemic heart disease. N Engl J Med 1995;332:706-11.
28. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993;290:33-40.
29. Danser AHJ, Schlekamp MADH, Bax WA, et al. Angiotensin converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-8.
30. Sasaki M, Oki T, Iuchi A, et al. Relationship between the angiotensin-converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996;14:1403-8.
31. Dudley C, Keavney B, Casadel B, Conway J, Bird R, Ratcliffe P. Prediction of patient response to antihypertensive drugs using genetic polymorphisms of the renin-angiotensin system genes. J Hypertens 1996;14:259-62.
32. Miziuri S, Hemmi H, Inoue A, et al. Renal haemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism. Nephron 1997;75:310-4.
33. van Essen GG, Rensma PL, de Zeeuw D, et al. Association between angiotensin converting enzyme gene and failure of renoprotective therapy. Lancet 1996;347:94-5.
34. Johnston CI, Jackson B, McGrath B, Matthews G, Arnolda L. Relationship of antihypertensive effect of enalapril to serum Mk422 levels and angiotensin converting enzyme inhibition. J Hypertens 1983:1(suppl 1):71-5.
35. Nussberger J, Fleck E, Bahrmann H, et al. Dose-related effects of ACE inhibition in man: quinalapril in patients with moderate congestive heart failure. Eur Heart J 1994:15(suppl D):113-22.
36. Brunner HR, Nussberger J, Waeber B. Dose-response relationships of ACE inhibitors and angiotensin II blockers. Eur Heart J 1994:15(suppl D): 123-8.
37. Ueda S, Morton JJ, Elliott HL, Connell JMC. Enhanced pressor response to angiotensin I in normotensive males with the deletion genotype (DD) of the angiotensin converting enzyme gene. Circulation 1995;25:1266-9.
38. Chadwick IG, O'Toole L, Morice AH, Yeo WW, Jackson PR, Ramsay LE. Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes. J Cardiovasc Pharmacol 1997;29:485-9.
39. Lachurie ML, Azizi M, Guyene TT, Alhenc-Gelas F, Menard J. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 1995;91: 2933-42.
40. Gottlieb SS, Robinson S, Wier M, et al. Determinants of the renal response to ACE inhibitors in patients with congestive heart failure. Am Heart J 1992;124:131-6.
41. Packer M, Lee WH, Kessler PD, et al. Identification of hyponatraemia as a risk factor for the development of functional renal insufficiency in severe chronic heart failure. J Am Coll Cardiol 1987;10:837-44.
42. Harden PN, Geddes C, Rowe PA, et al. Polymorphism in the angiotensin converting enzyme gene and progression of IgA nephropathy. Lancet 1995;345:1540-2.
43. Marre M, Bernadet P, Gallois Y, et al. Relationship between angiotensin 1 converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications Diabetes 1994;43: 384-8.
44. Miziuri S, Hemmi H, Inoue A, et al. Angiotensin converting enzyme polymorphism and development of diabetic nephropathy in NIDDM. Nephron 1995;70:455-9.